المؤلفون: Adeniran A. Haastrup, Marvin G. Chang, Daniel L. Southren, Russel J. Roberts, Edward A. Bittner, Alexa D. Nardone

المصدر: Nutrition in Clinical Practice

مصطلحات موضوعية: congenital, hereditary, and neonatal diseases and abnormalities, medicine.medical_specialty, Malabsorption, malabsorption, Ileus, 030309 nutrition & dietetics, Critical Illness, Medicine (miscellaneous), Gastroenterology, Enteral administration, 03 medical and health sciences, 0302 clinical medicine, Clinical Research, COVID‐19, Intensive care, Internal medicine, medicine, Humans, gastrointestinal function, Acetaminophen, Retrospective Studies, 0303 health sciences, Nutrition and Dietetics, SARS-CoV-2, business.industry, COVID-19, Retrospective cohort study, medicine.disease, Intestinal Absorption, Cohort, 030211 gastroenterology & hepatology, Gastrointestinal function, business, medicine.drug

الوصف: Objective Gastrointestinal (GI) dysfunction is prevalent in critically ill patients with coronavirus disease 2019 (COVID-19). The acetaminophen absorption test (AAT) has been previously described as a direct method for assessment of GI function. Our study determines whether the AAT can be used to assess GI function in critically ill COVID-19 patients, compared with traditional measures of GI function. Design Retrospective observational study of critically ill patients with COVID-19. Setting Three intensive care units at a tertiary care academic medical center. Patients Twenty critically ill patients with COVID-19. Interventions The results of AAT and traditional measures for assessing GI function were collected and compared. Measurements and main results Among the study cohort, 55% (11 of 20) of patients had evidence of malabsorption by AAT. Interestingly, all patients with evidence of malabsorption by AAT had clinical evidence of bowel function, as indicated by stool output and low gastric residuals during the prior 24 h. When comparing patients with a detectable acetaminophen level (positive AAT) with those who had undetectable acetaminophen levels (negative AAT), radiologic evidence of ileus was less frequent (20 vs 88%; P = .03), tolerated tube-feed rates were higher (40 vs 10 ml/h; P =.01), and there was a trend toward lower gastric residual volumes (45 vs 830 ml; P =.11). Conclusion Malabsorption can occur in critically ill patients with COVID-19 despite commonly used clinical indicators of tube-feeding tolerance. The AAT provides a simple, rapid, and cost-effective mechanism by which enteral function can be efficiently assessed in COVID-19 patients.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd407ba1289fbcc4bfa2bbb3bd3dc609Test
https://doi.org/10.1002/ncp.10687Test

المؤلفون: Xiaoyong Fu, Shixia Huang, Resel Pereira, Nicholas J. Wang, Chad A. Shaw, Jorge S. Reis-Filho, Sarmistha Nanda, Anna Tsimelzon, Agostina Nardone, Vidyalakshmi Sethunath, Rachel Schiff, Laura M. Heiser, Britta Weigelt, Lukas M. Simon, Joe W. Gray, Carmine De Angelis, Tao Wang, Mothaffar F. Rimawi, Lanfang Qin, Gary C. Chamness, Obi L. Griffith, Jamunarani Veeraraghavan, Huizhong Hu, C. Kent Osborne, Susan G. Hilsenbeck

المساهمون: Sethunath, Vidyalakshmi, Hu, Huizhong, DE ANGELIS, Carmine, Veeraraghavan, Jamunarani, Qin, Lanfang, Wang, Nichola, Simon, Lukas M, Wang, Tao, Fu, Xiaoyong, Nardone, Agostina, Pereira, Resel, Nanda, Sarmistha, Griffith, Obi L, Tsimelzon, Anna, Shaw, Chad, Chamness, Gary C, Reis-Filho, Jorge S, Weigelt, Britta, Heiser, Laura M, Hilsenbeck, Susan G, Huang, Shixia, Rimawi, Mothaffar F, Gray, Joe W, Osborne, C Kent, Schiff, Rachel

المصدر: Mol Cancer Res
Mol. Cancer Res. 17, 2318-2330 (2019)

مصطلحات موضوعية: 0301 basic medicine, Cancer Research, Geranylgeranyl pyrophosphate, Receptor, ErbB-2, Farnesyl pyrophosphate, Mevalonic Acid, Antineoplastic Agents, Apoptosis, Breast Neoplasms, Mechanistic Target of Rapamycin Complex 1, Lapatinib, Article, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Cell Line, Tumor, Survivin, Humans, Medicine, Phosphorylation, skin and connective tissue diseases, neoplasms, Molecular Biology, business.industry, Cell growth, Trastuzumab, 030104 developmental biology, Oncology, chemistry, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Cancer research, Female, Mevalonate pathway, Growth inhibition, business, Signal Transduction, medicine.drug

الوصف: Despite effective strategies, resistance in HER2+ breast cancer remains a challenge. While the mevalonate pathway (MVA) is suggested to promote cell growth and survival, including in HER2+ models, its potential role in resistance to HER2-targeted therapy is unknown. Parental HER2+ breast cancer cells and their lapatinib-resistant and lapatinib + trastuzumab–resistant derivatives were used for this study. MVA activity was found to be increased in lapatinib-resistant and lapatinib + trastuzumab–resistant cells. Specific blockade of this pathway with lipophilic but not hydrophilic statins and with the N-bisphosphonate zoledronic acid led to apoptosis and substantial growth inhibition of R cells. Inhibition was rescued by mevalonate or the intermediate metabolites farnesyl pyrophosphate or geranylgeranyl pyrophosphate, but not cholesterol. Activated Yes-associated protein (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ) and mTORC1 signaling, and their downstream target gene product Survivin, were inhibited by MVA blockade, especially in the lapatinib-resistant/lapatinib + trastuzumab–resistant models. Overexpression of constitutively active YAP rescued Survivin and phosphorylated-S6 levels, despite blockade of the MVA. These results suggest that the MVA provides alternative signaling leading to cell survival and resistance by activating YAP/TAZ–mTORC1–Survivin signaling when HER2 is blocked, suggesting novel therapeutic targets. MVA inhibitors including lipophilic statins and N-bisphosphonates may circumvent resistance to anti-HER2 therapy warranting further clinical investigation. Implications: The MVA was found to constitute an escape mechanism of survival and growth in HER2+ breast cancer models resistant to anti-HER2 therapies. MVA inhibitors such as simvastatin and zoledronic acid are potential therapeutic agents to resensitize the tumors that depend on the MVA to progress on anti-HER2 therapies.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a47e32d952d195af7dec86930048dfc3Test
https://doi.org/10.1158/1541-7786.mcr-19-0756Test

المؤلفون: Marasco, G, Colecchia, A, Bacchi Reggiani ML, Celsa, C, Farinati, F, Giannini, Eg, Benevento, F, Rapaccini, Gl, Caturelli, E, Di Marco, M, Biasini, E, Marra, F, Morisco, F, Foschi, Fg, Zoli, M, Gasbarrini, A, Baroni, Gs, Masotto, A, Sacco, R, Raimondo, G, Azzaroli, F, Mega, A, Vidili, G, Brunetto, Mr, Nardone, G, Dajti, E, Ravaioli, F, Avanzato, F, Festi, D, Trevisani, F, group, Italian Liver Cancer (ITA. LI. CA.

المساهمون: Marasco G., Colecchia A., Bacchi Reggiani M.L., Celsa C., Farinati F., Giannini E.G., Benevento F., Rapaccini G.L., Caturelli E., Di Marco M., Biasini E., Marra F., Morisco F., Foschi F.G., Zoli M., Gasbarrini A., Baroni G.S., Masotto A., Sacco R., Raimondo G., Azzaroli F., Mega A., Vidili G., Brunetto M.R., Nardone G., Dajti E., Ravaioli F., Avanzato F., Festi D., Trevisani F., Marasco, G., Colecchia, A., Bacchi Reggiani, M. L., Celsa, C., Farinati, F., Giannini, E. G., Benevento, F., Rapaccini, G. L., Caturelli, E., Di Marco, M., Biasini, E., Marra, F., Morisco, F., Foschi, F. G., Zoli, M., Gasbarrini, A., Baroni, G. S., Masotto, A., Sacco, R., Raimondo, G., Azzaroli, F., Mega, A., Vidili, G., Brunetto, M. R., Nardone, G., Dajti, E., Ravaioli, F., Avanzato, F., Festi, D., Trevisani, F.

مصطلحات موضوعية: Oncology, Male, Survival, Hepatocellular carcinoma, Cohort study, Hepatocellular carcinoma, Prognosis, Sorafenib, Survival, Severity of Illness Index, Antineoplastic Agent, 0302 clinical medicine, Prospective Studies, Liver Neoplasms, Gastroenterology, Middle Aged, Sorafenib, Prognosis, Treatment Outcome, Italy, Liver Neoplasm, 030220 oncology & carcinogenesis, Cohort, 030211 gastroenterology & hepatology, Female, Liver cancer, Cohort study, medicine.drug, medicine.medical_specialty, Carcinoma, Hepatocellular, Prognosi, Settore MED/12 - GASTROENTEROLOGIA, Antineoplastic Agents, Risk Assessment, 03 medical and health sciences, Internal medicine, medicine, Humans, neoplasms, Prognostic models, Neoplasm Staging, Proportional Hazards Models, Retrospective Studies, Hepatology, business.industry, Settore MED/09 - MEDICINA INTERNA, Gold standard, medicine.disease, digestive system diseases, Multicenter study, business

الوصف: Background: Sorafenib is the gold standard therapy for the advanced hepatocellular carcinoma (HCC). No scoring/staging is universally accepted to predict the survival of these patients. Aims: To evaluate the accuracy of the available prognostic models for HCC to predict the survival of advanced HCC patients treated with Sorafenib included in the Italian Liver Cancer (ITA.LI.CA.) multicenter cohort. Methods: The performance of several prognostic scores was assessed through a Cox regression-model evaluating the C-index and the Akaike Information Criterion (AIC). Results: Data of 1129 patients were analyzed. The mean age of patients was 61.6 years, and 80.8% were male. During a median follow-up period of 13 months, 789 patients died. The median period of Sorafenib administration was 4 months. All the prognostic scores were able to predict the overall survival (p

وصف الملف: ELETTRONICO

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8dadf7662451833197fdc66d47ecdf02Test
http://hdl.handle.net/11577/3401821Test

المؤلفون: Sormani, Maria P., Nicola De Rossi, Irene, Schiavetti, Luca, Carmisciano, Cinzia, Cordioli, Lucia, Moiola, Marta, Radaelli, Paolo, Immovilli, Marco, Capobianco, Maria, Trojano, Paola, Zaratin, Gioacchino, Tedeschi, Giancarlo, Comi, Battaglia, Mario A., Francesco, Patti, Marco, Salvetti, Agostino, Nozzolillo, Alessandra, Bellacosa, Alessandra, Protti, Alessia Di Sapio, Alessio, Signori, Alfredo, Petrone, Alvino, Bisecco, Aniello, Iovino, Anna, Dutto, Anna Maria Repice, Antonella, Conte, Antonio, Bertolotto, Antonio, Bosco, Antonio, Gallo, Antonio, Zito, Arianna, Sartori, Bruno, Giometto, Carla, Tortorella, Carlo, Antozzi, Carlo, Pozzilli, Chiara Rosa Mancinelli, Chiara, Zanetta, Christian, Cordano, Cinzia, Scandellari, Clara, Guaschino, Claudio, Gasperini, Claudio, Solaro, Cristina, Fioretti, Daiana, Bezzini, Damiano, Marastoni, Damiano, Paolicelli, Domizia, Vecchio, Doriana, Landi, Elisabetta, Bucciantini, Elisabetta, Pedrazzoli, Elisabetta, Signoriello, Elvira, Sbragia, Emanuela Laura Susani, Erica, Curti, Eva, Milano, Fabiana, Marinelli, Federico, Camilli, Filippo Martinelli Boneschi, Flora, Govone, Francesca, Bovis, Francesca, Calabria, Francesca, Caleri, Francesca, Rinaldi, Francesca, Vitetta, Francesco, Corea, Francesco, Crescenzo, Francesco, Teatini, Giulietta, Tabiadon, Franco, Granella, Giacomo, Boffa, Giacomo, Lus, Giampaolo, Brichetto, Giorgia Teresa Maniscalco, Giovanna, Borriello, Giovanna De Luca, Giovanna, Konrad, Giovanna, Vaula, Girolama Alessandra Marfia, Giulia, Mallucci, Giuseppe, Liberatore, Giuseppe, Salemi, Giuseppina, Miele, Grazia, Sibilia, Ilaria, Pesci, Laura, Brambilla, Leonardo, Lopiano, Leonardo, Sinisi, Pasquali, Livia, Lorenzo, Saraceno, Luca, Chiveri, Luca, Mancinelli, Grimaldi, Luigi M. E., Luisa Maria Caniatti, Marco Della Cava, Marco, Onofrj, Marco, Rovaris, Marco, Vercellino, Margherita Monti Bragadin, Maria, Buccafusca, Maria Chiara Buscarinu, Maria Grazia Celani, Maria Grazia Grasso, Maria Laura Stromillo, Maria, Petracca, Maria Pia Amato, Maria Pia Sormani, Maria Rita L'Episcopo, Maria, Sessa, Maria Teresa Ferrò, Maria Vittoria Ercolani, Mariangela, Bianco, Marianna Lo Re, Marika, Vianello, Marinella, Clerico, Mario Alberto Battaglia, Mario di Napoli, Marta, Ponzano, Marta Zaffira Conti, Massimiliano, Calabrese, Massimiliano, Mirabella, Massimo, Filippi, Matilde, Inglese, Matteo, Lucchini, Matteo, Pozzato, Maura Chiara Danni, Mauro, Zaffaroni, Mauro, Zampolini, Michela, Ponzio, Milena De Riz, Nicola De Stefano, Paola, Cavalla, Paola De Mitri, Paola, Grossi, Paolo, Confalonieri, Paolo, Gallo, Paolo, Ragonese, Patrizia, Sola, Pietro, Annovazzi, Pietro, Iaffaldano, Raffaele, Nardone, Raffaella, Cerqua, Raffaella, Clerici, Roberta, Lanzillo, Roberta, Motta, Roberto, Balgera, Roberto, Bergamaschi, Rocco, Totaro, Rosa, Iodice, Ruggero, Capra, Sabrina, Marangoni, Sabrina, Realmuto, Salvatore, Cottone, Sara, Montepietra, Sarah, Rasia, Sebastiano, Arena, Sebastiano, Bucello, Silvia, Banfi, Simona, Bonavita, Simona, Malucchi, Simone, Tonietti, Stefano, Vollaro, Susanna, Cordera, Umberto, Aguglia, Valentina Torri Clerici, Valeria, Barcella, Valeria, Bergamaschi, Vincenzo Brescia Morra, Vincenzo, Dattola, and Vittorio Mantero

المساهمون: Sormani, M. P., De Rossi, N., Schiavetti, I., Carmisciano, L., Cordioli, C., Moiola, L., Radaelli, M., Immovilli, P., Capobianco, M., Trojano, M., Zaratin, P., Tedeschi, G., Comi, G., Battaglia, M. A., Patti, F., Salvetti, M., P Sormani, Maria, De Rossi, Nicola, Schiavetti, Irene, Carmisciano, Luca, Cordioli, Cinzia, Moiola, Lucia, Radaelli, Marta, Immovilli, Paolo, Capobianco, Marco, Trojano, Maria, Zaratin, Paola, Tedeschi, Gioacchino, Comi, Giancarlo, A Battaglia, Mario, Patti, Francesco, Salvetti, Marco, Nozzolillo, Agostino, Bellacosa, Alessandra, Protti, Alessandra, Di Sapio, Alessia, Signori, Alessio, Petrone, Alfredo, Bisecco, Alvino, Iovino, Aniello, Dutto, Anna, Maria Repice, Anna, Conte, Antonella, Bertolotto, Antonio, Bosco, Antonio, Gallo, Antonio, Zito, Antonio, Sartori, Arianna, Giometto, Bruno, Tortorella, Carla, Antozzi, Carlo, Pozzilli, Carlo, Rosa Mancinelli, Chiara, Zanetta, Chiara, Cordano, Christian, Scandellari, Cinzia, Guaschino, Clara, Gasperini, Claudio, Solaro, Claudio, Fioretti, Cristina, Bezzini, Daiana, Marastoni, Damiano, Paolicelli, Damiano, Vecchio, Domizia, Landi, Doriana, Bucciantini, Elisabetta, Pedrazzoli, Elisabetta, Signoriello, Elisabetta, Sbragia, Elvira, Laura Susani, Emanuela, Curti, Erica, Milano, Eva, Marinelli, Fabiana, Camilli, Federico, Martinelli Boneschi, Filippo, Govone, Flora, Bovis, Francesca, Calabria, Francesca, Caleri, Francesca, Rinaldi, Francesca, Vitetta, Francesca, Corea, Francesco, Crescenzo, Francesco, Teatini, Francesco, Tabiadon, Giulietta, Granella, Franco, Boffa, Giacomo, Lus, Giacomo, Brichetto, Giampaolo, Teresa Maniscalco, Giorgia, Borriello, Giovanna, De Luca, Giovanna, Konrad, Giovanna, Vaula, Giovanna, Alessandra Marfia, Girolama, Mallucci, Giulia, Liberatore, Giuseppe, Salemi, Giuseppe, Miele, Giuseppina, Sibilia, Grazia, Pesci, Ilaria, Brambilla, Laura, Lopiano, Leonardo, Sinisi, Leonardo, Pasquali, Livia, Saraceno, Lorenzo, Chiveri, Luca, Mancinelli, Luca, E Grimaldi, Luigi M, Maria Caniatti, Luisa, Della Cava, Marco, Onofrj, Marco, Rovaris, Marco, Vercellino, Marco, Monti Bragadin, Margherita, Buccafusca, Maria, Chiara Buscarinu, Maria, Grazia Celani, Maria, Grazia Grasso, Maria, Laura Stromillo, Maria, Petracca, Maria, Pia Amato, Maria, Pia Sormani, Maria, Rita L'Episcopo, Maria, Sessa, Maria, Teresa Ferrò, Maria, Vittoria Ercolani, Maria, Bianco, Mariangela, Lo Re, Marianna, Vianello, Marika, Clerico, Marinella, Alberto Battaglia, Mario, di Napoli, Mario, Ponzano, Marta, Zaffira Conti, Marta, Calabrese, Massimiliano, Mirabella, Massimiliano, Filippi, Massimo, Inglese, Matilde, Lucchini, Matteo, Pozzato, Matteo, Chiara Danni, Maura, Zaffaroni, Mauro, Zampolini, Mauro, Ponzio, Michela, De Riz, Milena, De Stefano, Nicola, Cavalla, Paola, De Mitri, Paola, Grossi, Paola, Confalonieri, Paolo, Gallo, Paolo, Ragonese, Paolo, Sola, Patrizia, Annovazzi, Pietro, Iaffaldano, Pietro, Nardone, Raffaele, Cerqua, Raffaella, Clerici, Raffaella, Lanzillo, Roberta, Motta, Roberta, Balgera, Roberto, Bergamaschi, Roberto, Totaro, Rocco, Iodice, Rosa, Capra, Ruggero, Marangoni, Sabrina, Realmuto, Sabrina, Cottone, Salvatore, Montepietra, Sara, Rasia, Sarah, Arena, Sebastiano, Bucello, Sebastiano, Banfi, Silvia, Bonavita, Simona, Malucchi, Simona, Tonietti, Simone, Vollaro, Stefano, Cordera, Susanna, Aguglia, Umberto, Torri Clerici, Valentina, Barcella, Valeria, Bergamaschi, Valeria, Brescia Morra, Vincenzo, Dattola, Vincenzo, Mantero, Vittorio, Mp, Sormani, N, De Rossi, I, Schiavetti, L, Carmisciano, C, Cordioli, L, Moiola, M, Radaelli, P, Immovilli, M, Capobianco, M, Trojano, P, Zaratin, G, Tedeschi, G, Comi, Ma, Battaglia, F, Patti, M, Salvetti, Study Group Agostino Nozzolillo, Musc-19, Grimaldi, Luigi M. E., Vittorio Mantero, And, Nozzolillo, A., Bellacosa, A., Protti, A., Di Sapio, A., Signori, A., Petrone, A., Bisecco, A., Iovino, A., Dutto, A., Repice, A. M., Conte, A., Bertolotto, A., Bosco, A., Gallo, A., Zito, A., Sartori, A., Giometto, B., Tortorella, C., Antozzi, C., Pozzilli, C., Mancinelli, C. R., Zanetta, C., Cordano, C., Scandellari, C., Guaschino, C., Gasperini, C., Solaro, C., Fioretti, C., Bezzini, D., Marastoni, D., Paolicelli, D., Vecchio, D., Landi, D., Bucciantini, E., Pedrazzoli, E., Signoriello, E., Sbragia, E., Susani, E. L., Curti, E., Milano, E., Marinelli, F., Camilli, F., Boneschi, F. M., Govone, F., Bovis, F., Calabria, F., Caleri, F., Rinaldi, F., Vitetta, F., Corea, F., Crescenzo, F., Teatini, F., Tabiadon, G., Granella, F., Boffa, G., Lus, G., Brichetto, G., Maniscalco, G. T., Borriello, G., De Luca, G., Konrad, G., Vaula, G., Marfia, G. A., Mallucci, G., Liberatore, G., Salemi, G., Miele, G., Sibilia, G., Pesci, I., Brambilla, L., Lopiano, L., Sinisi, L., Pasquali, L., Saraceno, L., Chiveri, L., Mancinelli, L., Grimaldi, L. M. E., Caniatti, L. M., Cava, M. D., Onofrj, M., Rovaris, M., Vercellino, M., Bragadin, M. M., Buccafusca, M., Buscarinu, M. C., Celani, M. G., Grasso, M. G., Stromillo, M. L., Petracca, M., Amato, M. P., L'Episcopo, M. R., Sessa, M., Ferro, M. T., Ercolani, M. V., Bianco, M., Re, M. L., Vianello, M., Clerico, M., di Napoli, M., Ponzano, M., Conti, M. Z., Calabrese, M., Mirabella, M., Filippi, M., Inglese, M., Lucchini, M., Pozzato, M., Danni, M. C., Zaffaroni, M., Zampolini, M., Ponzio, M., De Riz, M., De Stefano, N., Cavalla, P., De Mitri, P., Grossi, P., Confalonieri, P., Gallo, P., Ragonese, P., Sola, P., Annovazzi, P., Iaffaldano, P., Nardone, R., Cerqua, R., Clerici, R., Lanzillo, R., Motta, R., Balgera, R., Bergamaschi, R., Totaro, R., Iodice, R., Capra, R., Marangoni, S., Realmuto, S., Cottone, S., Montepietra, S., Rasia, S., Arena, S., Bucello, S., Banfi, S., Bonavita, S., Malucchi, S., Tonietti, S., Vollaro, S., Cordera, S., Aguglia, U., Clerici, V. T., Barcella, V., Bergamaschi, V., Morra, V. B., Dattola, V., Mantero, V., Sormani M.P., De Rossi N., Schiavetti I., Carmisciano L., Cordioli C., Moiola L., Radaelli M., Immovilli P., Capobianco M., Trojano M., Zaratin P., Tedeschi G., Comi G., Battaglia M.A., Patti F., Salvetti M., Nozzolillo A., Bellacosa A., Protti A., Di Sapio A., Signori A., Petrone A., Bisecco A., Iovino A., Dutto A., Repice A.M., Conte A., Bertolotto A., Bosco A., Gallo A., Zito A., Sartori A., Giometto B., Tortorella C., Antozzi C., Pozzilli C., Mancinelli C.R., Zanetta C., Cordano C., Scandellari C., Guaschino C., Gasperini C., Solaro C., Fioretti C., Bezzini D., Marastoni D., Paolicelli D., Vecchio D., Landi D., Bucciantini E., Pedrazzoli E., Signoriello E., Sbragia E., Susani E.L., Curti E., Milano E., Marinelli F., Camilli F., Boneschi F.M., Govone F., Bovis F., Calabria F., Caleri F., Rinaldi F., Vitetta F., Corea F., Crescenzo F., Teatini F., Tabiadon G., Granella F., Boffa G., Lus G., Brichetto G., Maniscalco G.T., Borriello G., De Luca G., Konrad G., Vaula G., Marfia G.A., Mallucci G., Liberatore G., Salemi G., Miele G., Sibilia G., Pesci I., Brambilla L., Lopiano L., Sinisi L., Pasquali L., Saraceno L., Chiveri L., Mancinelli L., Grimaldi L.M.E., Caniatti L.M., Cava M.D., Onofrj M., Rovaris M., Vercellino M., Bragadin M.M., Buccafusca M., Buscarinu M.C., Celani M.G., Grasso M.G., Stromillo M.L., Petracca M., Amato M.P., L'Episcopo M.R., Sessa M., Ferro M.T., Ercolani M.V., Bianco M., Re M.L., Vianello M., Clerico M., di Napoli M., Ponzano M., Conti M.Z., Calabrese M., Mirabella M., Filippi M., Inglese M., Lucchini M., Pozzato M., Danni M.C., Zaffaroni M., Zampolini M., Ponzio M., De Riz M., De Stefano N., Cavalla P., De Mitri P., Grossi P., Confalonieri P., Gallo P., Ragonese P., Sola P., Annovazzi P., Iaffaldano P., Nardone R., Cerqua R., Clerici R., Lanzillo R., Motta R., Balgera R., Bergamaschi R., Totaro R., Iodice R., Capra R., Marangoni S., Realmuto S., Cottone S., Montepietra S., Rasia S., Arena S., Bucello S., Banfi S., Bonavita S., Malucchi S., Tonietti S., Vollaro S., Cordera S., Aguglia U., Clerici V.T., Barcella V., Bergamaschi V., Morra V.B., Dattola V., Mantero V.

المصدر: Annals of Neurology
Annals of neurology, vol 89, iss 4

مصطلحات موضوعية: Male, 0301 basic medicine, Dimethyl Fumarate, Neurodegenerative, multiple sclerosis, coronavirus, pneumonia, Severity of Illness Index, law.invention, Immunosuppressive Agent, Immunologic Factor, 0302 clinical medicine, Natalizumab, law, Monoclonal, Multiple Sclerosi, 80 and over, Lung, Humanized, Research Articles, Aged, 80 and over, Middle Aged, Intensive care unit, Hospitalization, Settore MED/26 - NEUROLOGIA, Intensive Care Units, Neurology, Methylprednisolone, Neurological, Pneumonia & Influenza, Interferon, Female, Immunosuppressive Agents, Research Article, Human, medicine.drug, Adult, medicine.medical_specialty, Musc-19 Study Group, Multiple Sclerosis, Adolescent, Clinical Sciences, Intensive Care Unit, Clinical Neurology, Settore MED/26, Antibodies, Monoclonal, Humanized, Autoimmune Disease, Antibodies, Young Adult, 03 medical and health sciences, Clinical Research, Internal medicine, Severity of illness, medicine, Humans, Immunologic Factors, Mortality, Aged, COVID-19, Fingolimod Hydrochloride, Interferons, SARS-CoV-2, Neurology & Neurosurgery, Expanded Disability Status Scale, business.industry, Multiple sclerosis, Neurosciences, Pneumonia, Odds ratio, medicine.disease, Brain Disorders, Good Health and Well Being, 030104 developmental biology, Ocrelizumab, Neurology (clinical), business, 030217 neurology & neurosurgery

الوصف: Objective: This study was undertaken to assess the impact of immunosuppressive and immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID-19) in people with multiple sclerosis (PwMS). Methods: We retrospectively collected data of PwMS with suspected or confirmed COVID-19. All the patients had complete follow-up to death or recovery. Severe COVID-19 was defined by a 3-level variable: mild disease not requiring hospitalization versus pneumonia or hospitalization versus intensive care unit (ICU) admission or death. We evaluated baseline characteristics and MS therapies associated with severe COVID-19 by multivariate and propensity score (PS)-weighted ordinal logistic models. Sensitivity analyses were run to confirm the results. Results: Of 844 PwMS with suspected (n = 565) or confirmed (n = 279) COVID-19, 13 (1.54%) died; 11 of them were in a progressive MS phase, and 8 were without any therapy. Thirty-eight (4.5%) were admitted to an ICU; 99 (11.7%) had radiologically documented pneumonia; 96 (11.4%) were hospitalized. After adjusting for region, age, sex, progressive MS course, Expanded Disability Status Scale, disease duration, body mass index, comorbidities, and recent methylprednisolone use, therapy with an anti-CD20 agent (ocrelizumab or rituximab) was significantly associated (odds ratio [OR] = 2.37, 95% confidence interval [CI] = 1.18–4.74, p = 0.015) with increased risk of severe COVID-19. Recent use (

وصف الملف: STAMPA; application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::658c28946b5a50bfdcddd11f665918f8Test
http://hdl.handle.net/11591/444794Test

المؤلفون: Chris I. Ardern, Steven E.S. Miner, Mary C. McCarthy, Heather Edgell, Massimo Nardone, Lynne E. Nield, Olga Toleva

المصدر: CJC Open
CJC Open, Vol 3, Iss 2, Pp 133-141 (2021)

مصطلحات موضوعية: lcsh:Diseases of the circulatory (Cardiovascular) system, medicine.medical_specialty, business.industry, Odds ratio, Adenosine, chemistry.chemical_compound, Coronary circulation, medicine.anatomical_structure, chemistry, lcsh:RC666-701, Exertional chest pain, Left atrial, Internal medicine, medicine, Cardiology, Uric acid, Dobutamine, Original Article, Cardiology and Cardiovascular Medicine, business, Acetylcholine, medicine.drug

الوصف: Background: It is unclear whether the coronary microvascular responses to multiple, mechanistically distinct hyperaemic agents exert similar dilatory responses or share common clinical predictors. This study therefore sought to characterize the index of microvascular resistance (IMR) response to multiple hyperaemic agents in the human coronary circulation. Methods: Thermodilution-derived IMR was determined during intravenous adenosine, intracoronary acetylcholine, and intravenous dobutamine in patients with ischemic symptoms and nonobstructive coronary angiograms. A total of 128 patients were studied (44 with adenosine and acetylcholine, and 84 with all agents). Adenosine IMR >25, acetylcholine IMR >31, and dobutamine IMR >29 were used to define elevated responses. Results: IMR responses demonstrated weak-to-moderate association (adenosine vs acetylcholine IMR: ρ = 0.33; adenosine vs dobutamine IMR: ρ = 0.51; acetylcholine vs dobutamine IMR: ρ = 0.28; all P < 0.01). Logistic regression analyses revealed that: (1) elevated adenosine IMR was associated with increasing age and left ventricle hypertrophy (odds ratio [OR] = 1.27 and 1.58; both P < 0.05, respectively), (2) elevated acetylcholine IMR was associated with increasing plasma uric acid (OR = 1.09; P < 0.05), and (3) elevated dobutamine IMR was associated with hypertension and left atrial volume index (OR = 3.99 and 1.07; both P < 0.05, respectively). Subset analyses to evaluate clinical utility of the acetylcholine and dobutamine IMR, independent of abnormal adenosine IMR, revealed that elevated acetylcholine and/or dobutamine IMR were associated with higher risk exercise stress tests, left atrial volumes, and burden of exertional chest pain. Conclusions: Microvascular-specific IMR responses to different hyperaemic agents are only moderately associated, whereas the predictors for agent-specific IMR responses varied, suggesting that multiple pharmacologic agents interrogate different microvascular control mechanisms. Résumé: Contexte: On ne sait pas vraiment si les réponses microvasculaires coronariennes à de multiples agents hyperémiques aux modes d’action distincts ont des effets vasodilatateurs similaires ou partagent des facteurs prédictifs cliniques communs. Cette étude visait donc à caractériser la réponse selon l’indice de résistance microvasculaire (IMR) aux multiples agents hyperémiques dans la circulation coronarienne chez l’humain. Méhodologie: L’IMR obtenu par thermodilution a été déterminé pendant l’administration intraveineuse d’adénosine, intracoronarienne d’acétylcholine et intraveineuse de dobutamine chez des patients présentant des symptômes ischémiques et par angiogrammes coronariens non obstructifs. Un total de 128 patients (44 avec l’adénosine et l’acétylcholine, et 84 avec tous les agents) ont fait partie de l’étude. Des réponses élevées étaient définies par un IMR à l’adénosine > 25, un IMR à l’acétylcholine > 31 et un IMR à la dobutamine > 29. Résultats: Les réponses selon l’IMR ont révélé une association faible à modérée (IMR à l’adénosine vs IMR à l’acétylcholine : ρ = 0,33; IMR à l’adénosine vs IMR à la dobutamine : ρ = 0,51; IMR à l’acétylcholine vs IMR à la dobutamine : ρ = 0,28; tous : p < 0,01). Des analyses de régression logistique ont révélé que : 1) un IMR à l’adénosine élevé était associé à l’avancement en âge et à une hypertrophie ventriculaire gauche (rapport des cotes [RC] = 1,27 et 1,58; p < 0,05 respectivement pour les deux), 2) un IMR à l’acétylcholine élevé était associé à l’augmentation de la concentration plasmatique d’acide urique (RC = 1,09; p < 0,05) et 3) un IMR à la dobutamine élevé était associé à l’hypertension et à l’indice de volume auriculaire gauche (RC = 3,99 et 1,07; p < 0,05 respectivement pour les deux). Des analyses par sous-groupes visant à évaluer l’utilité clinique de l’IMR à l’acétylcholine et à la dobutamine, indépendamment d’un IMR à l’adénosine anormal, ont révélé que des IMR à l’acétylcholine et/ou à la dobutamine élevés étaient associés à une augmentation du risque lors des épreuves à l’effort, à un volume auriculaire gauche plus élevé et à une augmentation du fardeau associé à la douleur thoracique à l’effort. Conclusions: Les réponses microvasculaires selon l’IMR à différents agents hyperémiques sont seulement modérément associées, alors que les facteurs prédictifs des réponses selon l’IMR spécifique de l’agent varient, ce qui laisse croire que les multiples agents pharmacologiques font appel à différents mécanismes de contrôle microvasculaire.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::729c96e9ea1cf456f005132b609e38eaTest
http://europepmc.org/articles/PMC7893196Test

المؤلفون: C. Mucherino, Rocco Maurizio Zagari, Agnese Miranda, Luciana Avallone, Franco Bazzoli, Lorenzo Romano, A. Romiti, Carmelina Loguercio, Katerina Priadko, Debora Compare, Lucia Granata, Marco Martorano, Marco Romano, Antonietta Gerarda Gravina, Alessandro Federico, Concetta Tuccillo, Gerardo Nardone, Maria Raffaella Romito, D. Sgambato, Marcello Dallio

المساهمون: Romano, M., Gravina, A. G., Nardone, G., Federico, A., Dallio, M., Martorano, M., Mucherino, C., Romiti, A., Avallone, L., Granata, L., Priadko, K., Compare, D., Tuccillo, C., Romito, M. R., Sgambato, D., Miranda, A., Romano, L., Loguercio, C., Bazzoli, F., Zagari, R. M., Romano M., Gravina A.G., Nardone G., Federico A., Dallio M., Martorano M., Mucherino C., Romiti A., Avallone L., Granata L., Priadko K., Compare D., Tuccillo C., Romito M.R., Sgambato D., Miranda A., Romano L., Loguercio C., Bazzoli F., Zagari R.M.

المصدر: HelicobacterREFERENCES. 25(4)

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Gastroenterology, Drug Administration Schedule, Helicobacter Infections, Internal medicine, Clarithromycin, Clarithromycin resistance, Drug Resistance, Bacterial, Medicine, Humans, Helicobacter, antimicrobial resistance, Adverse effect, High prevalence, biology, Helicobacter pylori, business.industry, non-bismuth quadruple therapy, General Medicine, Middle Aged, biology.organism_classification, bacterial infections and mycoses, Pylera, Anti-Bacterial Agents, Regimen, Infectious Diseases, Treatment Outcome, Case-Control Studies, Patient Compliance, Drug Therapy, Combination, Female, Antacids, business, Life study, Bismuth, medicine.drug

الوصف: Background: Bismuth quadruple (BQT) and non-bismuth quadruple (N-BQT) therapies are the recommended first-line treatments for Helicobacter (H.) pylori infection. Objective: To compare the efficacy of BQT and N-BQT in clinical practice in an area with high clarithromycin resistance, choosing the regimen on the basis of previous exposure to clarithromycin. Methods: A total of 404 consecutive Hpylori-positive, naïve patients were enrolled. A total of 203 patients without previous exposure to clarithromycin received N-BQT, 100 patients for 10days and 103 for 14days, whereas 201 with previous exposure to clarithromycin received 10-day BQT. Efficacy and treatment-related adverse events were assessed. Results and Conclusions: Eradication rates by intention-to-treat analysis were 88.2% for N-BQT and 91.5% for BQT (P=.26); per-protocol analysis eradication rates were 91.2% and 95.8% for N-BQT and BQT, respectively (P=.07). Eradication rates were significantly higher with 14-day than 10-day CT (P 

وصف الملف: STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59b1588c5fe875eb3f34e2eac5f922c6Test
https://pubmed.ncbi.nlm.nih.gov/32314519Test

المؤلفون: Valerio Nardone, Rocco Giannicola, Giovanna Bianco, Diana Giannarelli, Paolo Tini, Pierpaolo Pastina, Antonia Consuelo Falzea, Sebastiano Macheda, Michele Caraglia, Amalia Luce, Silvia Zappavigna, Luciano Mutti, Luigi Pirtoli, Antonio Giordano, Pierpaolo Correale

المساهمون: Nardone, V., Giannicola, R., Bianco, G., Giannarelli, D., Tini, P., Pastina, P., Falzea, A. C., Macheda, S., Caraglia, M., Luce, A., Zappavigna, S., Mutti, L., Pirtoli, L., Giordano, A., Correale, P.

المصدر: Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)

مصطلحات موضوعية: 0301 basic medicine, Cancer Research, medicine.medical_specialty, Durvalumab, Salvage therapy, Pembrolizumab, Gastroenterology, Procalcitonin, Avelumab, 03 medical and health sciences, 0302 clinical medicine, Atezolizumab, Internal medicine, prognostic factors of response, medicine, cell death receptor, Lung cancer, programmed cell death ligand-1, RC254-282, Original Research, business.industry, bacterial infection, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, inflammatory markers, inflammatory marker, real-world salvage therapy, bacterial infections, immune-check point blockade, procalcitonin, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Nivolumab, business, medicine.drug

الوصف: Peripheral-immune-checkpoint blockade (P-ICB) with mAbs to PD-1 (nivolumab and pembrolizumab) or PD-L1 (atezolizumab, durvalumab, avelumab) alone or combination with chemotherapy represents a novel active treatment for mNSCLC patients. However, this therapy can be associated to immune-related adverse events (irAEs) and high cost. Therefore, finding reliable biomarkers of response and irAEs is strongly encouraged to accurately select patients who may potentially benefit from the immuno-oncological treatment. This is a retrospective multi-institutional analysis performed on ninety-five mNSCLC patients who received real-world salvage therapy with nivolumab or atezolizumab between December 2015 and April 2020. The outcome of these patients in term of PFS and OS was evaluated in comparison with different serum levels of C-reactive protein (CRP), Erythrocyte Sedimention Rate (ESR) and Procalcitonin (PCT) by performing Kaplan–Meier and Log-rank test and multivariate analysis. We found that high baseline levels of CRP, ESR, and PCT were strongly predictive of poor outcome (P vs. those with just one marker over the cut off vs. those with both markers over the cut off: 40 ± 59 vs. 15.5 ± 5.5 vs. 5.5 ± 1.6 months, respectively; P

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cbc2d28bc8b055476a3a290898f44b4Test
https://pubmed.ncbi.nlm.nih.gov/34195086Test

المؤلفون: Agostina Nardone, Rachel Schiff, Henry Brown, Meghana V. Trivedi, Martin Shea, Mark Pilling, Jamunarani Veeraraghavan, Chandandeep Nagi, Rinath Jeselsohn, Carmine De Angelis, Oona Delpuech, Maria Letizia Cataldo, Tamika Mitchell, C. Kent Osborne, Mothaffar F. Rimawi, Hazel M. Weir, Gary C. Chamness, Xiaoyong Fu, Susan G. Hilsenbeck

المساهمون: Pilling, Mark [0000-0002-7446-6597], Apollo - University of Cambridge Repository, Nardone, A., Weir, H., Delpuech, O., Brown, H., De Angelis, C., Cataldo, M. L., Fu, X., Shea, M. J., Mitchell, T., Veeraraghavan, J., Nagi, C., Pilling, M., Rimawi, M. F., Trivedi, M., Hilsenbeck, S. G., Chamness, G. C., Jeselsohn, R., Osborne, C. K., Schiff, R.

المصدر: British Journal of Cancer

مصطلحات موضوعية: Cancer Research, Indoles, Neoplasms, Hormone-Dependent, Breast Neoplasms, Article, 03 medical and health sciences, chemistry.chemical_compound, Mice, MCF-7 Cell, 0302 clinical medicine, Breast cancer, Cinnamate, In vivo, medicine, Animals, Humans, Receptor, skin and connective tissue diseases, Fulvestrant, Cancer, Cell Proliferation, Estradiol, Animal, Cell growth, Estrogens, medicine.disease, Estrogen, Metastatic breast cancer, 3. Good health, Tamoxifen, Oncology, chemistry, Receptors, Estrogen, Indole, Cell culture, Cinnamates, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Cancer research, MCF-7 Cells, Heterografts, Female, Growth inhibition, Heterograft, Breast Neoplasm, Human, medicine.drug

الوصف: BACKGROUND: The oestrogen receptor (ER) is an important therapeutic target in ER-positive (ER+) breast cancer. The selective ER degrader (SERD), fulvestrant, is effective in patients with metastatic breast cancer, but its intramuscular route of administration and low bioavailability are major clinical limitations. METHODS: Here, we studied the pharmacology of a new oral SERD, AZD9496, in a panel of in vitro and in vivo endocrine-sensitive and -resistant breast cancer models. RESULTS: In endocrine-sensitive models, AZD9496 inhibited cell growth and blocked ER activity in the presence or absence of oestrogen. In vivo, in the presence of oestrogen, short-term AZD9496 treatment, like fulvestrant, resulted in tumour growth inhibition and reduced expression of ER-dependent genes. AZD9496 inhibited cell growth in oestrogen deprivation-resistant and tamoxifen-resistant cell lines and xenograft models that retain ER expression. AZD9496 effectively reduced ER levels and ER-induced transcription. Expression analysis of short-term treated tumours showed that AZD9496 potently inhibited classic oestrogen-induced gene transcription, while simultaneously increasing expression of genes negatively regulated by ER, including genes potentially involved in escape pathways of endocrine resistance. CONCLUSIONS: These data suggest that AZD9496 is a potent anti-oestrogen that antagonises and degrades ER with anti-tumour activity in both endocrine-sensitive and endocrine-resistant models.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1307add3c66d5075ec69b579adb4aedTest
http://europepmc.org/articles/PMC6353941Test

المؤلفون: Bruno Amato, Antonio M. Risitano, Debora Compare, C. Sgamato, Gerardo Nardone, Alba Rocco

المساهمون: Rocco, A., Compare, D., Risitano, A. M., Sgamato, C., Amato, B., Nardone, G.

مصطلحات موضوعية: Male, medicine.medical_specialty, Physiology, Hemoglobinuria, Paroxysmal, Jaundice, Gastroenterology, Hypertransaminasemia, Hepatitis, Young Adult, Complement inhibitor, Bone Marrow, hemic and lymphatic diseases, Internal medicine, medicine, Humans, Aplastic anemia, Paroxysmal nocturnal hemoglobinuria, business.industry, Anemia, Aplastic, Hepatology, Eculizumab, medicine.disease, medicine.anatomical_structure, Bone marrow, medicine.symptom, business, medicine.drug, Acute hepatiti

الوصف: Hepatitis-associated aplastic anemia is a well-recognized clinical syndrome in which marrow failure follows the development of hepatitis. Although aplastic anemia is intimately related to paroxysmal nocturnal hemoglobinuria, until now, no cases of PNH-associated hepatitis have been described. We report a case of recurrent acute hepatitis preceding the clinical onset of PNH. Treatment of PNH with the complement inhibitor eculizumab (Soliris®) prevented both recurrences of episodes of intravascular hemolysis and liver enzyme alteration. This is the first known published case of PNH-associated hepatitis.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c2674ccd8f6844ce0fe51e476381d9fTest
http://hdl.handle.net/11588/823809Test

المؤلفون: Raul Prados-Manzano, Grainne Holleran, Spyridon Michopoulos, Stefania Chetcuti Zammit, Santiago Frago, Erwin J M van Geenen, Deirdre McNamara, Joost P.H. Drenth, Karina V. Grooteman, Lia C. M. J. Goltstein, Gerardo Nardone, Mourad Benallaoua, Giuseppe Scaglione, Robert Benamouzig, Paulo S Salgueiro, Thomas Aparicio, Reena Sidhu, Wietske Kievit, Alba Rocco

المساهمون: Goltstein, L. C. M. J., Grooteman, K. V., Rocco, A., Holleran, G., Frago, S., Salgueiro, P. S., Aparicio, T., Scaglione, G., Chetcuti Zammit, S., Prados-Manzano, R., Benamouzig, R., Nardone, G., Mcnamara, D., Benallaoua, M., Michopoulos, S., Sidhu, R., Kievit, W., Drenth, J. P. H., van Geenen, E. J. M.

المصدر: Lancet Gastroenterology & Hepatology, 6, 11, pp. 922-932
Lancet Gastroenterology & Hepatology, 6, 922-932

مصطلحات موضوعية: medicine.medical_specialty, Gastrointestinal Diseases, MEDLINE, Octreotide, Other Research Radboud Institute for Molecular Life Sciences [Radboudumc 0], Lanreotide, Peptides, Cyclic, law.invention, Angiodysplasia, chemistry.chemical_compound, Randomized controlled trial, Gastrointestinal Agents, law, Internal medicine, medicine, Humans, Hepatology, business.industry, Gastroenterology, Patient data, Somatostatin, Treatment Outcome, Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], chemistry, Meta-analysis, Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5], business, Erythrocyte Transfusion, Gastrointestinal Hemorrhage, medicine.drug, Cohort study

الوصف: Item does not contain fulltext BACKGROUND: Gastrointestinal angiodysplasias are vascular malformations that often cause red blood cell transfusion-dependent anaemia. Several studies suggest that somatostatin analogues might decrease rebleeding rates, but the true effect size is unknown. We therefore aimed to investigate the efficacy of somatostatin analogues on red blood cell transfusion requirements of patients with gastrointestinal angiodysplasias and to identify subgroups that might benefit the most from somatostatin analogue therapy. METHODS: We did a systematic review and individual patient data meta-analysis. We searched MEDLINE, Embase, and Cochrane on Jan 15, 2016, with an updated search on April 25, 2021. All published randomised controlled trials and cohort studies that reported on somatostatin analogue therapy in patients with gastrointestinal angiodysplasias were eligible for screening. We excluded studies without original patient data, single case reports, small case series (ie

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0b9a4a28cb0092c5587a5d5fd3cef63Test
https://hdl.handle.net/11588/902308Test